描述CDK4/6抑制剂的心血管毒性:一个真实世界的药监测研究
Jae Hyun Kim1,2
1School of Pharmacy and Institute of New Drug Development, Jeonbuk National University, Jeonju 54896, Republic of Korea.
Cancers
|August 29, 2024
概括
用于乳腺癌的环素依赖性激酶4和6 (CDK4/6) 抑制剂与心力衰竭和高血压等心脏问题有关. 需要进一步的研究来了解这些心血管风险.
科学领域:
- 在瘤学瘤学.
- 心脏病学 心脏病学
- 药物监督 药物监督 药物监督
背景情况:
- 循环素依赖性激酶4和6 (CDK4/6) 抑制剂是激素受体阳性,HER2阴性乳腺癌的标准治疗方法.
- CDK4/6抑制剂的心血管安全概况需要进一步阐明.
- 了解与这些向治疗相关的心脏事件对于患者管理至关重要.
研究的目的:
- 系统地描述与CDK4/6抑制剂相关的心脏不良事件.
- 为了确定与palbociclib,ribociclib和abemaciclib相关的特定心血管毒性.
- 评估心血管事件的安全信号,使用已建立的药物监测方法.
主要方法:
- 对2015年第一季度至2024年第一季度的FDA不良事件报告系统 (FAERS) 数据的分析.
- 包括palbociclib,ribociclib或abemaciclib是主要可疑药物的报告.
- 信号检测算法的应用:比例报告比率 (PRR),报告几率比率 (ROR) 和信息组件 (IC).
主要成果:
- 总共审查了69,139份报告,其中2065份记录了心脏不良事件.
- 高血压和心力衰竭是最常见的心血管毒性报告.
- 确认了 ribociclib 和 QT 延长的安全信号被重新识别出来 (PRR 8.43, ROR 8.65, IC025 2.86).
结论:
- 使用CDK4/6抑制剂与显著的心血管不良事件有关,包括心力衰竭和高血压.
- 这些发现强调了在接受CDK4/6抑制剂的患者中需要警的心脏监测的必要性.
- 需要进一步研究CDK4/6抑制剂相关心脏毒性的潜在机制和危险因素.
更多相关视频
14:03High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers
Published on: March 24, 2023
1.8K
10:01High-Throughput Optical Controlling and Recording Calcium Signal in iPSC-Derived Cardiomyocytes for Toxicity Testing and Phenotypic Drug Screening
Published on: March 31, 2022
3.1K
相关概念视频
01:19Pharmacovigilance
789
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
789
02:34Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K